Form 4: MapLight Therapeutics Director Receives Equity Awards

Troy Cox, a director at MapLight Therapeutics, Inc., was granted restricted stock units and stock options on June 23, 2026, as part of the company's non-employee director compensation policy.

Summary

• Troy Cox, a director of MapLight Therapeutics, Inc., received a grant of 7,864 restricted stock units (RSUs) and a stock option to purchase 29,804 shares of common stock.
• The RSUs and stock options were granted on June 23, 2026, under the company's 2025 Equity Incentive Plan.
• These awards are part of the company's non-employee director compensation policy.
• The RSUs and stock options will vest in three equal annual installments, beginning on June 23, 2027, contingent upon Mr. Cox's continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine director compensation rather than significant operational or financial news.

Positives

• Director compensation aligns with long-term service through vesting schedules.
• Grant of equity awards indicates continued confidence in the company's future by a board member.

Risks

• Vesting is contingent on continued service, meaning failure to remain employed or serve as director will result in forfeiture of awards.
• The value of the stock options is subject to market fluctuations and the company's stock performance.

Future Outlook

The RSUs and stock options granted will vest over three years, indicating a long-term incentive structure tied to continued service.

Industry Context

StockSavvy.ai notes that the issuance of equity awards to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning director incentives with shareholder value creation and encouraging long-term commitment.

Stakeholder Impact

• Shareholders: The equity awards align director interests with long-term shareholder value, but the dilutive effect of options should be considered.
• Employees: Standard practice for director compensation, reinforcing governance structures.
• Management: Reinforces the company's compensation philosophy for its board.

Next Steps

• Vesting of RSUs and stock options will occur in three equal annual installments starting June 23, 2027, subject to continued service.

Key Dates

Keywords

Form 4, SEC Filing, MapLight Therapeutics, MPLT, Director Compensation, Equity Awards, Restricted Stock Units, Stock Options, Insider Trading, Beneficial Ownership